Multiple Myeloma

Ashley E. Rosko, MD, reviews unmet needs and treatment sequencing for patients with multiple myeloma.

Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.

Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.

An expert panel discusses the management of dysgeusia associated with bispecific antibodies in treating patients with multiple myeloma.

Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.

Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.

Experts on multiple myeloma present the case of a 61-year-old with relapsed/refractory multiple myeloma (MM) treated with a BCMA bispecific antibody who develops dysgeusia and offer their initial impressions.

Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.

A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.

Among those with multiple myeloma, Hispanic patients may experience worse outcomes such as in-hospital mortality vs other ethnic groups.

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.

A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.

Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.

Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.

Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,

Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.

Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.

Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.

Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.

James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.